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tively. The mean body-mass index was 26.1 kg/m².In-hospital mortality was
1.84%. After 2-years follow up, the survival rate was 92.16% with an event-free
survival rate of 71.9%. In our population, elevated LVFP was found in 32.3%
of cases mainly in elderly (p=0.007), diabetic (p=0.041), patients with hyperten-
sion (p<0.001), with a history of myocardial infarction (p<0.001) and in Killip
3 or 4 class (p<0.001). Chronic kidney disease and anemia were also found pre-
dictive of elevated LVFP (p values of 0.007 and 0.016 respectively). An inter-
mediate or high GRACE score and LVEF< 45% are predictive of poor
prognosis. The additive prognostic value of LVFP was calculated and confirmed
in our study. In fact E/e’ ratio>15 improve the prognostic value of the combina-
tion of the GRACE score and LVEF with a chi² value of 54.74.
Conclusion: Our study confirms the additive prognostic value of LVFP in
addition to the GRACE risk score and LVEF in patients admitted for ACS
without ST segment elevation.
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Background: Although silent Atrial Fibrillation (AF) has been suggested
to be common in Acute myocardial infarction (AMI), the true incidence and
characteristics of silent AF in AMI remains unknown. We aim to assess silent
AF incidence and determinants, including left atrium parameters.
Methods and results: 581 consecutive AMI were prospectively analyzed
by Continuous ECG Scope Monitoring (CSM) for 48H after hospital admis-
sion. New onset AF was defined as at least 1 episode >30 sec, absence of
p waves, and irregular RR intervals on CSM or absence of p waves or irreg-
ular RR intervals on 12-lead ECG, without any duration criterion. Left Atrial
(LA) dimensions and Left Ventricular Ejection Fraction (LVEF) were deter-
mined on admission by echocardiography. We analyzed the study population
into 3 groups: No AF, silent AF (defined as asymptomatic episodes of AF
lasting at least >30 sec) and symptomatic AF (defined as symptomatic epi-
sodes of AF that lasted ≥12hours). Ninety-five (16.4%) patients had AF on
CSM, of whom 76 (80%) developed silent AF. Compared with No AF group,
patients with silent AF were older (80 vs 62 y; p<0.001), more frequently
women (45 vs 27%; p=0.006), hypertensive (76% vs 52%; p<0.001) but less
smoker (18% vs 38%; p<0.001). Moreover, they had significant LA enlarge-
ment based on indexed LA diameter (24.4 vs 20.3 mm/m²; p<0.001), and
indexed left atrial volume (LAVI) (36.12 vs 26.95 ml/ m²; p=0.002). They also
had impaired LVEF (46 vs 54%; p<0.001). By multivariate analysis, age (OR
(95%CI): 1.06 (1.03-1.09), CRP (OR (95%CI): 1.01( 1.00-1.02) and indexed
LA diameter (OR (95%CI): 2.37 (1.31-4.25) were predictors of silent AF. By
ROC curve analysis, LAVI at 26.88 ml/m² was the best cutoff value to predict
silent AF occurrence after AMI, with sensibility at 73% and specificity at 50%.
Conclusion: In this prospective study in routine clinical practice, silent AF
in AMI is very common and is mostly underdiagnosed by classical discon-
tinued serial ECG monitoring. Left atrial parameters assessed by echocardiog-
raphy, including indexed diameter and LAVI, should be evaluated on
admission to predict silent AF occurrence.
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Background: Optimal platelet reactivity (PR) inhibition is critical to pre-
vent thrombotic events in primary percutaneous coronary intervention (PCI).
We aimed to determine the relationship between high on-treatment platelet
reactivity (HTPR) and ST-elevation myocardial infarction (STEMI) following
a 600mg loading dose (LD) of clopidogrel.
Methods and results: We performed a prospective monocentre study
enrolling patients on clopidogrel undergoing PCI. The VASP index was used
to assess PR inhibition after clopidogrel LD. HTPR was defined according to
the consensus as a VASP index ≥50%. The present study included 833 patients
undergoing PCI. Most patients had PCI for an acute coronary syndrome
(58.7%). The mean VASP index was 50 ±23% with a large inter-individual
variability (range: 1-94%). Patients with a VASP index ≥50% were signifi-
cantly older (p= 0.03), with a higher BMI (p<0.001), more often diabetic
(p=0.03), taking omeprazole (p=0.03), admitted for an ACS and with a high
fibrinogen level compared to good responders (VASP<50%). In multivariate
analysis BMI, omeprazole use, acute coronary syndrome and high fibrinogen
level (p<0.001) remained significantly associated with HTPR. Of importance,
in this analysis STEMI was independently associated with HTPR when com-
pared with the other forms of ACS (NSTEMI and unstable angina) with an
odd ratio of 2.14 (95% CI: 1.3 –3.5; p=0.003). 
Conclusion: STEMI is associated with high on-treatment platelet reactivity
following 600 mg of clopidogrel. The present results suggest that 600 mg of
clopidogrel may not be able to achieve an optimal PR inhibition in STEMI
patients undergoing PCI and more potent drugs may be preferred.
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Objective: Benefits of statins in the long term follow-up of ST elevation
myocardial infarction (STEMI) have been established, but the short term ben-
efits of early statins prescription remain unproven, especially according to the
reperfusion result.
Aim of the study: to assess the benefit of early statins prescription in in-
hospital outcome of STEMI patients.
Methods: Between January 1995 and November 2011, 1388 patients
admitted for STEMI have been included in the MIRAMI (MonastIR Acute
Myocardial Infarction) registry. During this period, statins were introduced in
early management of STEMI patients. This enabled us subdivide patients,
after excluding those with missing treatment data, into 2 groups: early pre-
scribed statins group (n= 561) versus no statins prescribed group (n=804). We
compared in-hospital outcome between these two groups and among the sub-
groups of successful or failure reperfusion therapy.
Results: In the early statins prescription group, there was a significant
reduction of in-hospital mortality (12.1% vs 5.3%, p<0.001), ventricular
arrhythmias (5.3% vs 2.2%, p<0.001 for ventricular tachycardia, 5.6% vs
3.1%, p=0.03 for ventricular fibrillation), and atrial fibrillation (7.7% vs 5%,
p=0.049). When successful reperfusion (whatever the method is), mortality
was lower in the early statins prescription group (6.8% vs 1.8%, p=0.001).
This difference is less pronounced when reperfusion fails (16.1% vs 11%,
p=0.07).
Conclusion: Early statins prescription improves in-hospital outcome (mor-
tality, ventricular and supra-ventricular arrhythmias). This improvement is
much marked when reperfusion is successful with only a trend to beneficial
effect in case of reperfusion failure.
